Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL. The study's investigators identified a four-gene model that segregated patients with different survival probabilities. The estimated 24-month nonrelapse mortality was significantly lower in the CAR-T cohort than in the allogeneic HSCT cohort. The research shows an emerging target for the development of novel CAR T-cell immunotherapies. The researchers reported “high rates of durable responses” in most patients who were in high-risk disease subgroups. Idecabtagene vicleucel led to “deeper and more durable responses” than standard regimens in the KarMMa-3 trial. The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma. The results showed pembrolizumab was well tolerated, with 23.5% of patients achieving a complete response. All patients had a complete response after the first infusion, while 67% had a complete response after the second infusion.